B-cell & Hematologic Antigens

Cat. No.

A35941

CAS No.

3035710-69-8

Lixarkitug

Synonyms: AZD9829 antibody; INT-020

Lixarkitug is a humanized IgG1κ antibody that specifically targets the IL-3 receptor alpha chain (CD123). This antibody plays a crucial role in the modulation of immune responses and is utilized in research applications related to hematological malignancies and autoimmune disorders. Its specificity for IL-3Ra makes it a valuable tool for investigating pathways involving interleukin signaling and for developing potential therapeutic strategies.

Cat. No.

A57465

CAS No.

3055975-56-6

Furtisetabart

Furtisetabart is a humanized monoclonal antibody that specifically targets CD147, exhibiting significant anti-tumor activity. As a member of the human IgG4κ antibody subtype, it is well-suited for various research applications in oncology. This reagent can be effectively utilized for studies investigating tumor microenvironment interactions and therapeutic interventions involving CD147 modulation.

Cat. No.

AT0003

Anti-FLT3 Antibody (AGS62P)

Anti-FLT3 Antibody (AGS62P) is a high-affinity monoclonal antibody directed against human Fms-like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase frequently overexpressed or mutated in acute myelogenous leukemia (AML). AGS62P is specifically designed for use in antibody-drug conjugate (ADC) development and demonstrates selective binding to FLT3-expressing cells. Due to its targeted nature, AGS62P is an ideal candidate for research in FLT3-driven malignancies, including AML, and can be utilized in preclinical models to evaluate therapeutic efficacy, drug delivery, and receptor-specific cytotoxicity.

Cat. No.

AT0061

CAS No.

1453362-55-4

Lilotomab

Synonyms: HH1

Lilotomab (HH1) is a murine-derived monoclonal antibody targeting CD37, a protein predominantly expressed on the surface of B cells. This antibody has demonstrated the ability to reduce clonogenic survival, indicating its potential to inhibit the proliferation of cell colonies. Furthermore, Lilotomab exhibits significant anti-tumor activity, making it a valuable tool for research in oncology, particularly in studies focused on B-cell malignancies.

Cat. No.

AT0064

CAS No.

652153-01-0

Zanolimumab

Synonyms: Anti-Human CD4 Recombinant Antibody

Zanolimumab is a fully human monoclonal antibody that specifically targets CD4, a critical molecule in the T-cell receptor (TCR) signaling pathway. By binding to CD4, Zanolimumab effectively inhibits TCR signal transduction, impacting T-cell activation and function. This antibody is utilized in research focused on various immune-related conditions and cancers, including rheumatoid arthritis, psoriasis, melanoma, and both cutaneous and peripheral T-cell lymphoma. Its precise targeting makes it a valuable tool for studies aimed at understanding T-cell behavior and for developing therapeutic strategies against diseases mediated by T-cells.

Cat. No.

AT0066

CAS No.

395639-53-9

Aselizumab

Synonyms: HuDreg-55

Aselizumab (HuDreg-55) is a humanized IgG4 monoclonal antibody targeting L-selectin (CD62L), a cell adhesion molecule predominantly expressed on circulating neutrophils. L-selectin facilitates the migration of these cells to sites of injury via chemotaxis. Due to its mechanism of action, Aselizumab has been associated with an increased incidence of infections and leukopenia following trauma. This antibody is pivotal for research into immune response modulation and the potential therapeutic management of inflammatory conditions.

Cat. No.

AT0071

CAS No.

2415439-63-1

Suciraslimab

Synonyms: SM03

Suciraslimab is a human IgG1 κ monoclonal antibody targeting CD22. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0076

Anti-ICAM3/CD50 Antibody

The Anti-ICAM3/CD50 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the ICAM3/CD50 antigen. This antibody features a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145 kDa. For isotype control purposes, reference is made to the Human IgG1 kappa, Isotype Control, ensuring accurate experimental comparisons and validations.

Cat. No.

AT0077

CAS No.

1116433-11-4

Itolizumab

Synonyms: Anti-Human CD6 Recombinant Antibody

Itolizumab is a humanized recombinant monoclonal antibody specifically targeting the extracellular SRCR distal domain 1 of the CD6 antigen. This antibody effectively reduces T-cell proliferation and modulates immune response by inhibiting the production of key pro-inflammatory cytokines, including INF-γ, TNFα, and IL-6. Due to its specific action on immune modulation, Itolizumab is extensively utilized in research focused on inflammatory and autoimmune conditions such as psoriasis and rheumatoid arthritis, as well as in studies exploring therapeutic approaches for COVID-19.

Cat. No.

AT0078

CAS No.

192391-48-3

Tositumomab

Synonyms: Anti-Human CD20 Recombinant Antibody

Tositumomab is a murine monoclonal antibody of the IgG2a lambda isotype, specifically targeting the CD20 antigen present on both normal and malignant B lymphocytes. This antibody is designed for the precise identification and study of B-cell populations in various immunological and oncological research settings.

Cat. No.

AT0084

CAS No.

1461640-62-9

Isatuximab

Isatuximab is a monoclonal antibody designed to specifically target CD38, a transmembrane receptor and ectoenzyme prominently expressed on the surface of cells in hematological malignancies, particularly multiple myeloma (MM). This antibody exerts its antitumor effects through a variety of biological pathways, including antibody-dependent cellular-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and the direct induction of apoptosis independently of crosslinking. Additionally, Isatuximab directly inhibits the enzymatic activity of CD38, which plays a crucial role in numerous cellular processes. This multifaceted mechanism of action makes Isatuximab a valuable tool in the research and treatment of multiple myeloma and other CD38-related disorders.

Cat. No.

AT0089

CAS No.

216503-57-0

Alemtuzumab

Synonyms: Campath-IH

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody engineered to bind specifically to interleukin-13 (IL-13), effectively neutralizing its activity. This antibody is extensively utilized in the study of diseases characterized by IL-13 involvement, including asthma, atopic dermatitis, and pulmonary fibrosis. Tralokinumab's targeted mechanism of action and specificity for IL-13 make it a valuable tool in immunological and inflammatory research contexts.

Cat. No.

AT0092

CAS No.

339086-79-2

Rovelizumab

Rovelizumab is a humanized monoclonal antibody that targets the leukointegrin family, specifically the CD11/CD18 cell adhesion proteins. This antibody is designed for the study of various inflammatory and ischemic conditions, including multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI), and stroke. Rovelizumab's mechanism of action involves modulating leukocyte adhesion and migration, processes critical in the pathogenesis of these conditions. This makes Rovelizumab an essential tool for researchers investigating the cellular interactions and pathways underlying acute and chronic inflammatory responses.

Cat. No.

AT0095

CAS No.

3010940-29-8

Balertatug

Balertatug is a human IgG1 kappa monoclonal antibody specifically targeting CD70. This antibody serves as a precise tool for the study of CD70 expression and function in various immunological contexts. For appropriate experimental control, the corresponding isotype control is Human IgG1 kappa, Isotype Control, ensuring accurate interpretation of results.

Cat. No.

AT0109

CAS No.

2367001-70-3

Grisnilimab

Synonyms: WT1

Grisnilimab is an IgG2a monoclonal antibody targeting CD7, implicated in tumor suppression and relevant to the pathogenesis of Wilms' tumor. This antibody functions by regulating the transcription of various target genes and may also play a role in the post-transcriptional processing of RNA. Grisnilimab is designed for research applications focusing on the molecular mechanisms of tumorigenesis and potential therapeutic interventions.

Cat. No.

AT0116

Anti-MPL/TPOR/CD110 Antibody (TA136)

Synonyms: TA136

The Anti-MPL / TPOR / CD110 (TA136) antibody specifically binds to the tertiary structure of MPL, also known as thrombopoietin receptor or CD110. This monoclonal antibody recognizes MPL with high specificity, making it a valuable tool in the study of MPL's role in signaling pathways that regulate platelet production. Its potential therapeutic applications include the treatment of congenital amegakaryocytic thrombocytopenia, a disorder characterized by platelet deficiency. This antibody is suitable for a range of experimental applications, including flow cytometry, Western blotting, and immunohistochemistry.

Cat. No.

AT0117

CAS No.

1660159-36-3

Inotuzumab

Synonyms: Humanized Anti-CD22 Recombinant Antibody

Inotuzumab is a humanized recombinant antibody of the IgG4, κ isotype, specifically designed to target human CD22. This antibody can be conjugated with the cytotoxic agent ozogamicin, forming an antibody-drug conjugate (ADC) utilized in research focused on acute lymphoblastic leukemia and non-Hodgkin lymphoma. Inotuzumab's precise targeting mechanism facilitates the delivery of therapeutic agents directly to malignant cells, thereby enhancing the efficacy and specificity of treatment modalities under investigation.

Cat. No.

AT0126

CAS No.

637334-45-3

Ocrelizumab

Ocrelizumab (Ocrevus) is a humanized monoclonal antibody targeting CD20, designed to deplete B cells. It operates primarily through antibody-dependent cellular cytotoxicity (ADCC), effectively inhibiting lesion formation in multiple sclerosis models in mice. This mechanism underscores its potential for application in research focused on autoimmune diseases and immunotherapy.

Cat. No.

AT0135

Ispectamab

Ispectamab is a human IgG1 κ monoclonal antibody specifically targeting TNFRSF17. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0137

Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13)

The Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) is a chimeric mouse IgG1 monoclonal antibody designed to specifically target human LFA-1α/CD11a. For accurate isotype control in experimental procedures, it is recommended to use Mouse IgG1 kappa, Isotype Control. This antibody serves as a critical tool for the study of immune cell activation and adhesion in various immunological research settings.

Cat. No.

AT0139

CAS No.

214745-43-4

Efalizumab

Efalizumab is a humanized monoclonal antibody that selectively targets CD11a, the α subunit of lymphocyte function-associated antigen 1 (LFA-1). By modulating T cell activity, Efalizumab effectively inhibits T cell activation, adhesion to keratinocytes, and trafficking to cutaneous sites. This antibody is particularly valuable for research into the pathophysiology and potential treatments of plaque psoriasis, offering insights into T cell-mediated skin disorders.

Cat. No.

AT0144

Anti-CD44 Antibody (Hermes-1)

The Anti-CD44 Antibody (Hermes-1) is a chimeric rat IgG2a, κ antibody designed to specifically target human CD44. This product is ideal for research focused on the cell-surface glycoprotein CD44, which is involved in cell-cell interactions, cell adhesion, and migration. For accurate experimental control, it is recommended to use the Rat IgG2a kappa Isotype Control.

Cat. No.

AT0149

Inebilizumab (FUT8-KO)

Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody engineered in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). This genetic modification results in a fucose-deficient antibody, significantly enhancing its antibody-dependent cellular cytotoxicity (ADCC) capabilities. Specifically designed to target CD19, Inebilizumab demonstrates increased efficacy in mediating ADCC against B cells. This product is ideal for advanced research applications focusing on immune-mediated diseases such as multiple sclerosis and neuromyelitis optica, providing a valuable tool for studies into the pathogenesis and treatment of these conditions.

Cat. No.

AT0152

CAS No.

1987854-08-9

Bersanlimab

Synonyms: BI-505

Bersanlimab (BI-505) is a fully human monoclonal antibody specifically designed to target and bind to intercellular adhesion molecule-1 (ICAM-1, also known as CD54). This antibody exhibits potent anticancer properties by interfering with ICAM-1 mediated cell adhesion, a process crucial for tumor progression and metastasis. Bersanlimab is utilized extensively in research focused on the development of therapeutic strategies for various cancers.

Cat. No.

AT0160

CAS No.

220578-59-6

Gemtuzumab ozogamicin

Gemtuzumab ozogamicin is a monoclonal IgG4-κ antibody specifically targeting the CD33 antigen, predominantly expressed on leukemic myeloblasts in acute myeloid leukemia (AML). This antibody serves as a foundational component for the synthesis of the antibody-drug conjugate (ADC), Gemtuzumab ozogamicin. This conjugate is composed of Gemtuzumab linked to a cytotoxic derivative of Calicheamicin, a potent antibiotic known for its antitumor activity. Gemtuzumab ozogamicin is primarily utilized in research focused on the therapeutic targeting and treatment modalities of acute myeloid leukemia.